Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 1
1953 1
1954 1
1956 1
1962 2
1965 3
1966 2
1967 4
1968 5
1969 10
1970 8
1971 12
1972 10
1973 16
1974 13
1975 41
1976 49
1977 68
1978 57
1979 68
1980 63
1981 68
1982 87
1983 94
1984 82
1985 76
1986 61
1987 73
1988 78
1989 80
1990 68
1991 74
1992 82
1993 92
1994 101
1995 92
1996 97
1997 102
1998 79
1999 107
2000 111
2001 135
2002 135
2003 157
2004 159
2005 210
2006 232
2007 237
2008 259
2009 250
2010 335
2011 383
2012 394
2013 351
2014 349
2015 336
2016 393
2017 488
2018 553
2019 637
2020 662
2021 690
2022 713
2023 731
2024 609

Text availability

Article attribute

Article type

Publication date

Search Results

10,218 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: ADa-Gracia, 20Cruz-Caparros
Page 1
C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB, Bomback AS. Ahmad SB, et al. Adv Chronic Kidney Dis. 2020 Mar;27(2):104-110. doi: 10.1053/j.ackd.2019.12.003. Adv Chronic Kidney Dis. 2020. PMID: 32553242 Review.
C3 glomerulopathy (C3G) is a rare set of kidney diseases with 2 patterns: C3 glomerulonephritis (C3GN) and dense deposit disease. ...Acquired or genetic alterations of the regulatory proteins of the complement pathway result in C3G. Although the disease is character …
C3 glomerulopathy (C3G) is a rare set of kidney diseases with 2 patterns: C3 glomerulonephritis (C3GN) and dense deposit disea …
C3 glomerulopathy.
Cook HT. Cook HT. F1000Res. 2017 Mar 10;6:248. doi: 10.12688/f1000research.10364.1. eCollection 2017. F1000Res. 2017. PMID: 28357053 Free PMC article. Review.
C3 glomerulopathy is a recently defined entity that encompasses a group of kidney diseases caused by abnormal control of complement activation with deposition of complement component C3 in glomeruli leading to variable glomerular inflammation. Before the recognition …
C3 glomerulopathy is a recently defined entity that encompasses a group of kidney diseases caused by abnormal control of complement a …
Assessment of the Role of C3(H(2)O) in the Alternative Pathway.
Fromell K, Adler A, Åman A, Manivel VA, Huang S, Dührkop C, Sandholm K, Ekdahl KN, Nilsson B. Fromell K, et al. Front Immunol. 2020 Mar 31;11:530. doi: 10.3389/fimmu.2020.00530. eCollection 2020. Front Immunol. 2020. PMID: 32296436 Free PMC article.
In this study we investigate the hydrolysis of C3 to C3(H(2)O) and its ability to initiate activation via the alternative pathway (AP) of the complement system. ...This results in the formation of non-proteolytically activated C3(H(2)O) which is believed have …
In this study we investigate the hydrolysis of C3 to C3(H(2)O) and its ability to initiate activation via the alternative path …
Recent insights into C3 glomerulopathy.
Barbour TD, Pickering MC, Cook HT. Barbour TD, et al. Nephrol Dial Transplant. 2013 Jul;28(7):1685-93. doi: 10.1093/ndt/gfs430. Epub 2013 Mar 10. Nephrol Dial Transplant. 2013. PMID: 23479095 Free PMC article. Review.
'C3 glomerulopathy' is a recent disease classification comprising several rare types of glomerulonephritis (GN), including dense deposit disease (DDD), C3 glomerulonephritis (C3GN) and CFHR5 nephropathy. ...The role of uncontrolled C3 activation in pathogenes …
'C3 glomerulopathy' is a recent disease classification comprising several rare types of glomerulonephritis (GN), including dense depo …
Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases.
Meuleman MS, Grunenwald A, Chauvet S. Meuleman MS, et al. Semin Immunol. 2022 Mar;60:101634. doi: 10.1016/j.smim.2022.101634. Epub 2022 Jul 8. Semin Immunol. 2022. PMID: 35817659 Review.
C3 glomerulopathy (C3G) is a rare and complex kidney disease that primarily affects young adults. ...However, the lack of sufficient efficiency in anti-C5 therapy highlights the extreme complexity of the disease and the need for new therapeutic approaches based on C3 …
C3 glomerulopathy (C3G) is a rare and complex kidney disease that primarily affects young adults. ...However, the lack of sufficient …
C3 Glomerulopathy: Novel Treatment Paradigms.
Tarragon Estebanez B, Bomback AS. Tarragon Estebanez B, et al. Kidney Int Rep. 2023 Dec 16;9(3):569-579. doi: 10.1016/j.ekir.2023.12.007. eCollection 2024 Mar. Kidney Int Rep. 2023. PMID: 38481517 Free PMC article. Review.
C3 glomerulopathy (C3G) is diagnosed by kidney biopsy, with immunofluorescence showing isolated or dominant C3 staining, indicating hyperactivity of the alternative complement pathway as the key driver of glomerular injury. ...
C3 glomerulopathy (C3G) is diagnosed by kidney biopsy, with immunofluorescence showing isolated or dominant C3 staining, indic …
C3 nephritic factors: A changing landscape.
Levy Erez D, Meyers KE, Sullivan KE. Levy Erez D, et al. J Allergy Clin Immunol. 2017 Jul;140(1):57-59. doi: 10.1016/j.jaci.2017.02.018. Epub 2017 Mar 16. J Allergy Clin Immunol. 2017. PMID: 28322851 Free PMC article. No abstract available.
Complement: you gutsy thing!
Kemper C. Kemper C. Trends Immunol. 2024 Apr;45(4):228-230. doi: 10.1016/j.it.2024.03.003. Epub 2024 Mar 26. Trends Immunol. 2024. PMID: 38538487
., validate this concept in the mouse gut, where extrahepatic, intestine-produced, and/or operative C3 protects against enteric infections....
., validate this concept in the mouse gut, where extrahepatic, intestine-produced, and/or operative C3 protects against enteric infec …
10,218 results
You have reached the last available page of results. Please see the User Guide for more information.